How were Proteon Therapeutics' earnings last quarter?

Proteon Therapeutics Inc (NASDAQ:PRTO) announced its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01.

What other stocks do shareholders of Proteon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Sierra Oncology (SRRA) , Agile Therapeutics (AGRX) , Biocept (BIOC) , Gilead Sciences (GILD) , ImmunoGen (IMGN) , Inovio Pharmaceuticals (INO) and Novavax (NVAX) .

NASDAQ:PRTO

Proteon Therapeutics (PRTO) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free PRTO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.66
▼
$2.89
50-Day Range: $0.84
▼
$25.13
52-Week Range: $0.22
▼
$3.94

Volume: 241,473 shs
Average Volume: 1.11 million shs
Market Capitalization: $60.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Proteon Therapeutics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Proteon Therapeutics Stock (NASDAQ:PRTO)

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

PRTO Stock News Headlines

February 2, 2024 | macrumors.com

iPad Pro

November 5, 2023 | morningstar.com

Esperion Therapeutics Inc ESPR

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

September 20, 2023 | benzinga.com

The Latest Analyst Ratings for Revance Therapeutics

June 7, 2023 | finance.yahoo.com

ENLV - Enlivex Therapeutics Ltd.

May 25, 2023 | benzinga.com

Prelude Therapeutics Insider Trades Send a Signal

May 23, 2023 | benzinga.com

Global Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives Growth

April 26, 2023 | benzinga.com

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

February 22, 2023 | benzinga.com

Early Adopter of Remote Therapeutic Monitoring Achieves Significant Clinical and Financial Outcomes

January 22, 2023 | finance.yahoo.com

Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)

January 19, 2023 | wsj.com

Advanced Proteome Therapeutics Announces Its Proposed Plan of Arrangement

January 19, 2023 | marketwatch.com

Peripheral Arterial Disease (PAD) Therapeutics Market 2023 Size & Segmentation Analysis with Share, Trends till 2028 [ NEW REPORT ]

January 3, 2023 | benzinga.com

Business & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patients

October 17, 2022 | msn.com

What 5 Analyst Ratings Have To Say About PTC Therapeutics

September 22, 2022 | msn.com

What 6 Analyst Ratings Have To Say About Revance Therapeutics

September 9, 2022 | finance.yahoo.com

Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022

June 15, 2022 | finance.yahoo.com

ProthioneTM Capsules Reduced Time to COVID-19 Clinical Resolution and Decreased Viral Load in Phase II Clinical Trial

June 3, 2022 | thestreet.com

Bristol-Myers To Buy Turning Point Therapeutics In $4.1 Billion Oncology Deal

May 27, 2022 | bizjournals.com

Flagship Pioneering launches protein startup with $75M

See More Headlines

Receive PRTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/31/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:PRTO
CUSIP: N/A
CIK: 1359931
Web: www.proteontherapeutics.com
Phone: 781-890-0102
Fax: N/A
Employees: 17
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -118.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.98
Quick Ratio: 5.98

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.06) per share
Price / Book: -45.83

Miscellaneous

Outstanding Shares: 22,179,000
Free Float: N/A
Market Cap: $60.99 million
Optionable: Not Optionable
Beta: 0.60

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Timothy P. Noyes (Age 57)
Pres, CEO & Director
Mr. George A. Eldridge (Age 56)
Sr. VP, CFO, Treasurer & Assistant Sec.
Dr. Steven Keith Burke (Age 58)
Sr. VP & Chief Medical Officer
Mr. Matthew P. Kowalsky (Age 46)
VP of Legal & Sec.
Mr. Bradley J. Hartman (Age 38)
VP of People

Key Competitors

View All Competitors

PRTO Stock Analysis - Frequently Asked Questions

How were Proteon Therapeutics' earnings last quarter?: Proteon Therapeutics Inc (NASDAQ:PRTO) announced its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01.
What other stocks do shareholders of Proteon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Sierra Oncology (SRRA), Agile Therapeutics (AGRX), Biocept (BIOC), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

This page (NASDAQ:PRTO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Proteon Therapeutics (PRTO) Stock Price, News & Analysis

About Proteon Therapeutics Stock (NASDAQ:PRTO)

PRTO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PRTO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info